Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(9%)
Results Posted
43%(3 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_4
1
9%
Ph not_applicable
1
9%
Ph phase_1
2
18%
Ph phase_3
1
9%
Ph phase_2
6
55%

Phase Distribution

2

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Terminated1
unknown1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 26 (54.5%)
Phase 31 (9.1%)
Phase 41 (9.1%)
N/A1 (9.1%)

Trials by Status

terminated19%
completed764%
unknown19%
recruiting19%
withdrawn19%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_2

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
terminatedphase_1

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

NCT04361812
completedphase_2

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

NCT00890162
completedphase_2

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

NCT02049294
completedphase_1

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

NCT00260702
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07059091Phase 2

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Recruiting
NCT04361812Phase 1

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Terminated
NCT00890162Phase 2

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Completed
NCT02049294Phase 2

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

Completed
NCT00260702Phase 1

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

Completed
NCT00096954Phase 4

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)

Completed
NCT00851370Phase 2

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

Withdrawn
NCT01803763Phase 2

Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients

Completed
NCT00314574Phase 3

A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

Completed
NCT01179529Phase 2

Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

Completed
NCT00286416Not Applicable

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11